Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.

Cytotherapy - 1 Jan 2006

Kokhaei P, Adamson L, Palma M, Osterborg A, Pisa P, Choudhury A, Mellstedt H

Abstract excerpt

BACKGROUND: The generation of Ag-loaded DC under good manufacturing practice (GMP) conditions is logistically challenging and further compounded when the starting precursors need to be purified from B-CLL patients who have overwhelming numbers of circulating B-CLL cells and decreased numbers of monocytes. METHODS: We have previously demonstrated that DC with endocytosed B-CLL apoptotic bodies are powerful...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Cryopreservation
Share to Dendritic Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunomagnetic Separation

Share to Interleukin-12

Share to Leukemia, B-Cell

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Monocytes

Source

Identifiers

PMID: 16923607
DOI: 10.1080/14653240600832656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.PMID 16923607Read ↗

Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.Semantic proximity Read ↗

Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.Semantic proximity Read ↗

Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells.Semantic proximity Read ↗

Clinical-scale generation of dendritic cells in a closed system.Semantic proximity Read ↗

In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy.Semantic proximity Read ↗

Simplified method to generate large quantities of dendritic cells suitable for clinical applications.Semantic proximity Read ↗

Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.Semantic proximity Read ↗

Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads.Semantic proximity Read ↗

Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells.Semantic proximity Read ↗

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.Semantic proximity Read ↗

CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination.Semantic proximity Read ↗

Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.